Aflibercept: the molecule

Name: Aflibercept: the molecule
Uploaded: 2015-09-29T12:06:00+00:00
Description: Dr Udaondo discusses the molecular structure and pharmacokinetic/pharmacodynamic properties of EYLEA, an anti-angiogenic agent to be approved for the treatment of wet AMD and macular edema secondary to central retinal vein occlusion (CRVO).

Search

Aflibercept: the molecule

Patricia Udaondo, MD

Show Description +

Dr Udaondo discusses the molecular structure and pharmacokinetic/pharmacodynamic properties of EYLEA, an anti-angiogenic agent to be approved for the treatment of wet AMD and macular edema secondary to central retinal vein occlusion (CRVO).

Posted: 9/29/2015

Aflibercept: the molecule

Patricia Udaondo, MD

Dr Udaondo discusses the molecular structure and pharmacokinetic/pharmacodynamic properties of EYLEA, an anti-angiogenic agent to be approved for the treatment of wet AMD and macular edema secondary to central retinal vein occlusion (CRVO).

Posted: 9/29/2015

Please log in to leave a comment.